Webb9 aug. 2024 · NEW YORK CITY (dpa-AFX) - Philip Morris International Inc. (PM) announced its acquisition of OtiTopic, a U.S. respiratory drug development company. OtiTopic has a … Webb9 aug. 2024 · RTTNews Aug. 9, 2024, 06:36 AM (RTTNews) - Philip Morris International Inc. (PM) announced its acquisition of OtiTopic, a U.S. respiratory drug development …
Philip Morris To Acquire OtiTopic - Quick Facts Nasdaq
Webb30 juni 2024 · LAUSANNE, Switzerland-- (BUSINESS WIRE)--Philip Morris International Inc. (PMI) (NYSE: PM) today announced its acquisition of OtiTopic, a U.S. respiratory drug development company with a late-stage inhalable acetylsalicylic acid (ASA) treatment for acute myocardial infarction. Webb30 juni 2024 · OtiTopic was founded in 2012 as an innovative pharmaceutical start-up company and holds several key patents, differentiated intellectual property, and has … incidents of gun violence crossword
Philip Morris International acquires inhaled drug specialist OtiTopic …
Webb9 aug. 2024 · OtiTopic was founded in 2012 as an innovative pharmaceutical start-up company and holds several key patents, differentiated intellectual property, and has confirmed a 505(b)2 pathway through constructive interactions with the FDA. PMI expects the impact of the acquisition of OtiTopic on its full-year 2024 adjusted diluted EPS to be … WebbTake a tour of the Cube, PMI's research and development center located in Neuchâtel, Switzerland. Along the way, learn about our smoke-free product assessment program … Webb10 aug. 2024 · Philip Morris International Inc. announced its acquisition of OtiTopic, a U.S. respiratory drug development company with a late-stage inhalable acetylsalicylic acid (ASA) treatment for acute myocardial infarction. If approved, the treatment can address the significant unmet medical need of the over 83 million people, in the U.S. alone, at … inconsistent health